抗VEGF药物及微创玻璃体手术在眼后段疾病治疗中的应用  

Application of anti-VEGF drugs and minimally invasive vitrectomy in the treatment of the diseases in posterior segment of eye

作　　者：蒋依琳 高洪瑞[2] 

机构地区：[1]温州医科大学眼视光学院,浙江温州325027 [2]济南军区总医院眼科,山东济南250031

出　　处：《实用医药杂志》2017年第6期557-560,共4页Practical Journal of Medicine & Pharmacy

摘　　要：眼后段相关疾病的临床治疗研究近年来取得了突飞猛进的发展,特别是抗血管内皮生长因子(VEGF)药物的广泛应用和微创玻璃体手术技术的不断完善,使糖尿病视网膜病变、年龄相关黄斑变性、眼后段疾病继发的新生血管性青光眼(NVG)和复杂眼外伤等眼后段相关疾病的治疗取得了巨大进步,现就抗VEGF药物、微创玻璃体手术的特性及应用于眼后段相关疾病治疗的进展进行扼要综述。In recent years,the clinical treatment of diseases related to posterior segment of eyes has made rapid development. Especially the widespread use of anti VEGF drugs and the continuous improvement of vitreous surgery minimally invasive technology,have made great progress in the treatment of diabetic retinopathy,age-related macular degeneration,eye＇s posterior segment disease secondary neovaseular glaucoma （NVG）,complicated ocular trauma and the other diseases related to posterior segment of the eyes,etc. In this paper,the characteristics of anti-VEGF drugs,minimally invasive vitrectomy and their application in the treatment of eye＇s posterior segment diseases are reviewed.

关 键 词：抗血管内皮生长因子药物 玻璃体手术 微创 眼后段 

分 类 号：R779.1[医药卫生—眼科] R775.3[医药卫生—临床医学]